CPA
KURA icon

Capital Performance Advisors’s Kura Oncology KURA Stock Holding History

Capital Performance Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-147
Closed -$2.87K – 1499
2024
Q3 		$2.87K Buy
+147
New +$2.98K ﹤0.01% 1376

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Performance Advisors's KURA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Kura Oncology (KURA) in Q4 2024, closing a stake of 147 shares — an estimated $2.87K sold.

Capital Performance Advisors first reported a position in KURA in Q3 2024 and held it in 1 quarter. The position peaked at $2.87K in Q3 2024. 185 funds tracked by Wall St. Rank hold KURA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Kura Oncology position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 147 Kura Oncology shares in Q4 2024, an estimated $2.87K.
  • Capital Performance Advisors first reported a position in Kura Oncology in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Kura Oncology position peaked at $2.87K in Q3 2024.
  • 185 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.